Suzhou Zelgen Biopharmaceuticals Co Ltd (688266.SS) stock: key figures, P/E, revenue and dividend
Health Care · Biotechnology · China · ISIN CNE100003RP1
Suzhou Zelgen Biopharmaceuticals Co Ltd financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 532.95 m CNY | 812.73 m CNY |
| Gross profit | 495.23 m CNY | 812.73 m CNY |
| Operating income | -155.04 m CNY | -165.76 m CNY |
| EBIT | -125.95 m CNY | -166.41 m CNY |
| Net income | -137.83 m CNY | -160.70 m CNY |
| Diluted EPS – continuing operations | -0.52 CNY | -0.61 CNY |
Full history since 2016, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Suzhou Zelgen Biopharmaceuticals Co Ltd
Suzhou Zelgen Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, and distribution of medicines in the People's Republic of China. The company offers donafenib tosylate tablets for liver cancer, hepatocellular carcinoma, and metastatic radioactive iodine-refractory differentiated thyroid cancer; and recombinant human thrombin for hemostasis. It also develops gecacitinib hydrochloride tablets for severe alopecia areata, moderate to severe atopic dermatitis, ankylosing spondylitis, moderate to severe plaque psoriasiste, idiopathic pulmonary fibrosis, and myelofibrosis; recombinant human thyroid-stimulating hormone for injection; and ZG006 for injection, indications for small cell lung cancer, neuroendocrine carcinoma, and other advanced tumors. In addition, it develops ZG005 for injection, which is in phase I/II clinical trial for cervical cancer, liver cancer, neuroendocrine carcinoma and other advanced tumors; and ZGGS18, ZGGS15, ZGGS34, ZG016, ZG2273, ZG2001film, and ZG0895 hydrochloric acid for injection indications for advance tumors. The company's products are used in multiple therapeutic areas, such as tumors and hematological diseases, bleeding and trauma, and immune inflammatory diseases. Suzhou Zelgen Biopharmaceuticals Co., Ltd. was founded in 2009 and is based in Kunshan, the People's Republic of China.
More stocks
- Siegfried Holding AG (SFZN.SW)
- Jinneng Holding Shanxi Coal Industry Co Ltd (601001.SS)
- Odakyu Electric Railway Co Ltd (9007.T)
- Rush Street Interactive, Inc. (RSI)
- Shijiazhuang Yiling Pharmaceutical Co Ltd (002603.SZ)
- ITRON, INC. (ITRI)
- ROBERT HALF INC. (RHI)
- Hess Midstream LP (HESM)
- AP Memory Technology Corp (6531.TW)
- City of London Investment Trust PLC (CTY.L)
- Envista Holdings Corp (NVST)
- Jiangxi Hongdu Aviation Industry Co Ltd (600316.SS)
Not investment advice. All data without warranty, price as of 23.10.2026. Details in the risk notice.